Brand-name drug companies could face new penalties if they push patients to a newer drug version to weaken generic or biosimilar competition. The FTC would get clearer power to sue, stop the conduct, and seek money back. Companies could still defend changes tied to safety, supply problems, or other valid reasons.
Modern Action shows what the legislation would change, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
Drug Competition Enhancement Act is a Senate bill waiting for floor action. The latest recorded action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.
Latest action on S. 1040: Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.
Who this affects: This bill mainly affects brand-name drug makers, generic drug companies, biosimilar makers, and the people and programs that pay for medicines. It matters most when a cheaper rival is close to entering the market and the brand-name company changes its product strategy. Patients, insurers, and government health programs could feel the effects if the bill leads to faster competition and lower prices.
Why this matters: This bill matters because patients and health plans often pay more when cheaper drugs cannot compete effectively. It tries to stop product changes that may keep brand-name prices high for longer by blocking or weakening generics and biosimilars. It also gives the FTC a clearer rule to enforce, instead of relying only on broader antitrust law. The real effect would depend on how often the FTC brings cases, how courts read the new language, and how drug companies change their behavior.
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
Officially: Drug Competition Enhancement Act
Brand-name drug companies could face new penalties if they push patients to a newer drug version to weaken generic or biosimilar competition. The FTC would get clearer power to sue, stop the conduct, and seek money back. Companies could still defend changes tied to safety, supply problems, or other valid reasons.
Use this page to support, oppose, or ask Congress to amend S.1040. Modern Action shows what the bill would change, helps identify the right senators or representative, and drafts a bill-specific message you can edit and send.
Where it stands
floor_pending
Your representatives are deciding where they stand. A few messages can tip the balance.
↓ Why your message matters here
This bill is moving through Congress right now — your representative needs to hear from you.
Enter your ZIP to see how your senators and member of Congress have voted, sponsored, or spoken on this bill.
The debate
Where this bill is in the process
Introduced
Introduced in Senate
Senate Committee
Under Senate committee consideration
Senate Floor Vote
Voted on by Senate
Latest: Placed on Senate Legislative Calendar under General Orders. Calendar No. 43. (4/10/2025)
Passed Senate
Approved by Senate
House Review
Sent to House for consideration
Passed Both Chambers
Approved by both House and Senate
Signed into Law
Signed by the President
For more detail
Choose one clear position: support, oppose, or amend. Then pick any reasons or personal context you want included. Modern Action uses that input and the bill context to draft a message you can edit and send.
Congressional offices prioritize messages from their own constituents. Modern Action uses your address to route the drafted message to your senators when that is the most relevant target for this bill.
The draft includes the bill number, your position, the reasons you selected, any personal context you added, and a direct ask such as voting yes, voting no, cosponsoring, opposing, or seeking changes. You stay in control because you can edit the message before sending.
This page gives you an opportunity to support, oppose, or ask for changes to Drug Competition Enhancement Act, then contact the elected officials who can act. Modern Action drafts the message from your position and the reasons you select.
Modern Action keeps the action tied to the bill itself: what it would do, where it is in the process (floor pending), which office can still act, and what ask belongs in the message.
You are not starting from a blank form. Modern Action drafts the message around S.1040, your stance, and the reasons you choose, then lets you edit and send when ready.
